Exelixis Looking Excellent

In the long-awaited American Society of Clinical Oncology abstracts that debuted this week, Rule Breakers pick Exelixis (Nasdaq: EXEL  ) was relatively well-represented, issuing multiple reports that showed promising progress in several of its anticancer compounds.

Nothing earth-shattering arose regarding Exelixis' data sets on its later-stage multitarget drugs like XL647, nor early-stage compounds such as XL184 and XL765. Still, all of Exelixis' compounds with abstracts at ASCO continued to show at least some activity in fighting cancer, and the phase 2 XL880 stomach cancer drug data particularly stood out.

Considering that Exelixis' lead drugs are only now entering late-stage testing, it's still too early to determine how its compounds will fare against the competition. (That's why I'm not yet directly comparing the company's data to that of rival compounds.) Nonetheless,  Exelixis' ASCO abstracts suggest that the safety and efficacy data for its drugs is definitely good enough to warrant future testing. Then again, GlaxoSmithKline's (NYSE: GSK  ) decision to pick up XL880 was a good clue that it merited further investigation.

Last week, IMS Health (NYSE: RX  ) estimated that cancer-drug sales could grow 67% between 2008 and 2012, to $80 billion worldwide. Exelixis' compounds, known as multiple tyrosine kinase inhibitors, attack cancer in a novel way that helps them stand out from the competition. However promising the ASCO data, however, the drugs' real test will come in subsequent trials, as survival data versus other compounds and other more comparable results arrive.

Further early-stage Foolishness:

Exelixis is an active pick of our market-beating Rule Breakers newsletter. You can check out all our recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.

GlaxoSmithKline is an active Income Investor pick.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Motley Fool owns shares of Exelixis. The Fool's disclosure policy needs no further testing.


Read/Post Comments (0) | Recommend This Article (19)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 648933, ~/Articles/ArticleHandler.aspx, 11/27/2014 7:33:24 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement